{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-307898","form_type":"8-K","ticker":"ATRA","cik":"0001604464","company_name":"Atara Biotherapeutics, Inc.","filed_at":"2022-12-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.379303+00:00","generated_at":"2026-06-21T02:33:32.400505+00:00","sec_items":["5.02","8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Atara gets EC approval for Ebvallo in EBV+ PTLD; board changes announced","bullets":["EC granted marketing authorization for Ebvallo (tabelecleucel) as monotherapy for relapsed/refractory EBV+ PTLD in adult/pediatric patients 2+ years.","Approval applies to all 27 EU member states plus Iceland, Norway, and Liechtenstein.","Directors Ronald C. Renaud and Roy Baynes resigned effective Dec 19, 2022; Carol D. Gallagher appointed Chair.","Board size reduced from ten to eight directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-307898","json":"https://secwatch.observer/filing/0001193125-22-307898.json","markdown":"https://secwatch.observer/filing/0001193125-22-307898.md","text":"https://secwatch.observer/filing/0001193125-22-307898.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604464/000119312522307898/0001193125-22-307898-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604464/000119312522307898/d437946d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T02:33:32.400505+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4795b2ede8","claim":"Carol D. Gallagher was appointed as Chair of the Board at Atara Biotherapeutics, Inc..","evidence_excerpt":"In addition, effective as of December 19, 2022, the Board appointed Carol D. Gallagher, Pharm D., an independent member of the Board, to succeed Mr. Renaud as Chair of the Board and, in accordance with Section 16 of the Company’s Second Amended and Restated Bylaws, reduced the number of directors on the Board from ten to eight directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1604464/000119312522307898/0001193125-22-307898-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chair of the Board"}],"fact_type":"executive_change"},{"claim_id":"921a85479e","claim":"Roy Baynes resigned as Director at Atara Biotherapeutics, Inc..","evidence_excerpt":"Also on December 16, 2022, Roy Baynes notified the Company of his resignation from the Board, effective as of December 19, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1604464/000119312522307898/0001193125-22-307898-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"9c8bf5d0a7","claim":"Ronald C. Renaud resigned as Director at Atara Biotherapeutics, Inc..","evidence_excerpt":"On December 16, 2022, Ronald C. Renaud notified Atara Biotherapeutics, Inc., a Delaware corporation (the “Company”), of his resignation from the Board of Directors of the Company (the “Board”), effective as of December 19, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1604464/000119312522307898/0001193125-22-307898-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}